| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 39.5 | 49.7 |
| Gross profit | 16.2 | 22.2 |
| Profit before tax | 0.3 | -8.1 |
| Net income | 0.2 | -7.7 |
| EPS (diluted, $ a share) | $0.00 | $-0.02 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -20.4% |
|---|---|
| Gross margin | 40.9% |
| Operating margin | -6.0% |
10-Q filed with the SEC, NASDAQ: AMRN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Amarin Corp Plc\Uk: key numbers
- Share price
- $11.31Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Amarin Corp Plc\Uk
All →Amarin Corp Plc\Uk Financial Results
Amarin Corporation reported Q3 2026 financial results, achieving positive net income of $0.2 million and a 44% reduction in operating expenses. The company highlighted strong international momentum with a 68% increase in European in-market demand for VAZKEPA and maintained a 47% share of the U.S. icosapent ethyl market.
“Our results in the third quarter demonstrate the continued positive trajectory in our operational, financial and strategic transformation, underscoring the progress we are making to strengthen our business, expand the value of our VASCEPA®/VAZKEPA® (icosapent ethyl, or IPE) franchise and deliver long-term shareholder value.”
Aaron Berg, President & Chief Executive Officer